Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 973 results for death

  1. Communication:- What are the most clinically effective and cost-effective methods of addressing patient and carer concerns about strong opioids, including anticipating and managing adverse effects, and engaging patients in prescribing decisions?

    especially morphine, can be negatively associated with adverse effects and death. To improve adherence and to enable patients and carers...

  2. What are the implications of FH for the safety of a mother during pregnancy and what are the risks of fetal malformations attributable to pharmacological therapies

    is also limited information on the risk of pregnancy (including cardiac death) in a woman with FH. Data on the incidence of cardiac...

  3. Signs and symptoms that predict neutropenic sepsis in the community:- A prospective study should be carried out to determine which signs and symptoms experienced by patients in the community predict neutropenic sepsis and the outcomes of these episodes.

    too narrow will delay the emergency treatment of infection and may lead to death, increased need for intensive or critical care...

  4. Perinatal palliative care:- What impact does timely perinatal palliative care have on the experience of bereaved parents?

    after birth.There is little evidence on the experience families have of the death of a baby with or without specific support from a...

  5. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.

  6. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

  7. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

  8. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

  9. Integrated patient information systems:- What is the clinical and cost effectiveness of different methods for integrating patient information throughout the emergency medical care pathway?

    multidisciplinary orcomplex care needs, and recognising a person's preferred place of death in palliative care. In many locations around...

  10. Prognostic tools:- Is the amyotrophic lateral sclerosis (ALS) Prognostic Index an accurate predictor of survival in people with MND under NHS care in England and/or Wales?

    being more aware of the likely progression and prepare themselves for the death of their loved one.Accurate predictions of survival...

  11. What is the optimal way of discharging people approaching the end of their life from hospitals back to their place of residence?

    the person's place of residence, such as a nursing home, especially when death is imminent. Such discharges are often delayed because of...

  12. Point-of-care coagulation testing:- What is the clinical and cost effectiveness of point-of-care coagulation testing using rotational thromboelastometry (ROTEM) or thromboelastography (TEG) to target treatment, compared with standard laboratory coagulation testing?

    coagulopathy could reduce mortality from haemorrhage, which is the main cause of death in patients with major trauma. Point-of-care...

  13. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.

  14. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.